HANNOVER
16.11.2015 17:31:45 CET | Business Wire | Press release
Cvent compiled this first annual list on the basis of data evaluation from conference planners and their levels of interaction with over 2,500 European hotels and locations. Data from July 2014 to June 2015 was taken into consideration. Hannover won points as a city in the heart of Europe with the largest exhibition grounds in the world and an exceptional and multi-faceted location.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151116006084/en/
Cvent is a leading cloud-based event management platform for companies. They offer software solutions for location selection, mobile apps for events, Web surveys as well as providing hotels with a platform for targeted advertising campaigns. The platform, which started in the USA, operates internationally and has a website and contact persons in Germany.
“We are in very good company in this ranking list and quite rightly so. Not only a modern infrastructure, central position, the largest exhibition grounds in the world and unique locations have helped the Hannover region to establish itself as a strong centre in the heart of Europe for events of all kinds,” commented Hans Christian Nolte, managing director of Hannover Marketing und Tourismus GmbH.
Hannover at the IBTM in Barcelona
International representation: HannoverKongress, the Deutsche Messe AG and the Hannover Congress Centrum (HCC) are exhibiting from 17 to 19 November under the motto “The Meeting Planet – Wide awake: day + night”.
Alongside IMEX, ibtm world held in Barcelona, is one of the most important trade fairs for the conference, incentive and business travel industry. Nearly 5,000 exhibitors from over 100 countries exhibit every year for around 15,500 trade visitors from the congress and incentive industry. The goals are simple – to provide the best B2B platform, supported by an excellent network and an extensive, global hosted buyer programme.
HannoverKongress
HannoverKongress is the partner for congresses and conferences in the Hannover region. The congress service of Hannover Marketing und Tourismus GmbH, helps customers to organise successful events with tailor-made solutions free of commission.
More information can found here: www.hannoverkongress.de/english and www.visit-hannover.com/en .
Visit Hannover – Trade Fairs 2016
CeBIT
2016
– Partner Country Switzerland: 14-18 March 2016
Hannover
Messe
– Partner Country USA: 25-29 April 2016
View source version on businesswire.com: http://www.businesswire.com/news/home/20151116006084/en/
Contact:
Hannover Marketing und Tourismus GmbH
Laura Harke, +49 511
12345-444 | Fax: +49 511 12345-445
info@hannoverkongress.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom